CoChat

Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon ? immunotherapy

Open access
Bielefeldt-Ohmann, H., Marzo, A. L., Himbeck, R. P., Jarnicki, A. G., Robinson, B. W. S., Fitzpatrick, D. R. · 1995 · Cancer Immunology Immunotherapy

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Abstract

A role for interleukin-6 (IL-6) in malignant mesothelioma has been suggested by the clinically presenting symptoms of mesothelioma patients, which include fever, weight loss and thrombocytosis. A murine model of malignant mesothelioma was therefore used to examine the potential role of IL-6 in this cancer type and whether the effect of interferon alpha (IFN alpha) therapy on mesothelioma might be mediated, in part, by regulating IL-6 levels and/or IL-6-induced pathobiology. A panel of human and murine mesothelioma cell lines was assayed for endogenous IL-6 production in a bioassay, and for IL-6-mRNA expression. Four out of 5 human and 5 out of 15 murine mesothelioma cell lines produced moderate to high levels of bioactive IL-6 in vitro. This result was corroborated by mRNA detection. One of the representative murine cell lines, AB22, was chosen for further in vivo studies in the murine mesothelioma model. In AB22-inoculated mice detectable serum IL-6 levels were found to precede macroscopically detectable tumour growth, clinical signs (cachexia, abdominal distension, diarrhoea) and changes in the peripheral lymphoid organs (cell depletion and functional depression). Treatment with anti-IL-6 antibody curtailed the clinical symptoms (P < 0.001), as did treatment with recombinant human (rhu) IFN alpha (P < 0.001). Neither anti-IL-6 antibody nor rhuIFN alpha had a direct growth-inhibitory effect on the AB22 mesothelioma cell line in vitro, however, in vivo rhuIFN alpha treatment of mice inoculated with AB22 cells attenuated both IL-6 mRNA expression in the tumours and serum IL-6 levels, ameliorated the depression of lymphocyte activities, and enhanced the number of tumour-infiltrating lymphocytes and macrophages. On the basis of these results it is suggested that IL-6 mediates some of these effects, directly or indirectly, and that a combination therapy of rhuIFN alpha and anti-IL-6 antibody may be an improved palliative treatment for patients with malignant mesothelioma.

Overview

Integrity signals

Registry

Crossref · 10.1007/bf01519898

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Research works printed but not linked: 1

  1. Musk AW, Bowman RV, Christmas TI, Robinson BWS. Management of malignant mesothelioma. In: Henderson DW, Shilkin KB, Langlois SLP, Whitaker D, editors. Malignant mesothelioma. New York: Hemisphere; 1992. pp. 292–302. [Google Scholar]

Cited by

See all 52

Metadata

Authors
Bielefeldt-Ohmann, H., Marzo, A. L., Himbeck, R. P., Jarnicki, A. G., Robinson, B. W. S., & Fitzpatrick, D. R.
Affiliations
The University of Western Australia (AU)
Venue
Cancer Immunology Immunotherapy
Published
1995-07
Volume
40
Issue
4
Pages
241-250
ISSN
  • 0340-7004 (ISSN-L)
  • 1432-0851
OpenAlex
W1980153171
Cited by
52
References
39
Citations by year
2025: 1 · 2024: 1 · 2023: 1 · 2021: 1 · 2019: 1 · 2018: 3 · 2016: 2 · 2015: 4 · 2014: 2 · 2012: 3
FWCI
2.77
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Cancer Immunology Immunotherapy (publishedVersion)
  • PubMed Central (publishedVersion)
  • UWA Profiles and Research Repository (University of Western Australia) (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
  • Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
  • Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
Keywords
interleukin-6, malignant mesothelioma, interferon-alpha, anti-IL-6 antibody, IL-6 mRNA expression, cachexia, lymphocyte depletion, tumor-infiltrating lymphocytes, tumour-associated macrophages, palliative care
MeSH terms
Interleukin-6 Inhibitors, Animals, Base Sequence, Female, Humans, Immunotherapy, Interferon Type I, Mesothelioma, Mice, Inbred BALB C, Molecular Sequence Data, Recombinant Proteins, RNA, Messenger, Tumor Cells, Cultured, Interleukin-6, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.